Nrx pharmaceuticals announces data safety monitoring board (dsmb) update on u.s. national institutes of health (nih) study of zyesami® (aviptadil) in critical covid-19

Based on a review of nearly 75% of the target enrollment of 640 patients, most of which have reached 90 days, the independent dsmb overseeing the activ-3b (tesico) study determined that evaluation of aviptadil should cease due to futility zyesami® (aviptadil) was the sole remaining investigational medicine in activ-3b targeted at critical covid-19 patients activ-3b critical care study evaluated zyesami and veklury® (remdesivir), in critical covid-19 patients, as monotherapy and in combination against placebo the dsmb stated there were no safety concerns for aviptadil radnor, pa. , may 25, 2022 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced results of a review conducted by the data safety and monitoring board (dsmb) on may 25, 2022.
NRXP Ratings Summary
NRXP Quant Ranking